Up To $755M Added To AZ Scuttled-Drug Damage Claim In Del.

A stockholder representative for former shareholders of biopharmaceutical company Syntimmune has proposed up to $755 million in additional damages after a Delaware vice chancellor found that an AstraZeneca PLC unit failed...

Already a subscriber? Click here to view full article